← Back to Search

Alpha-1 Adrenergic Receptor Antagonist

Pre-operative Tamsulosin and Time to Spontaneous Void After Hysterectomy

Phase 2
Waitlist Available
Research Sponsored by University of Arizona
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Women 18-80 undergoing outpatient minimally invasive hysterectomy
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks

Summary

This trial is testing if giving a single dose of tamsulosin before surgery can help women who are having a minimally invasive hysterectomy to urinate sooner and leave the hospital faster. Tamsulosin has been studied for its effectiveness in reducing postoperative urinary retention in various surgeries.

Eligible Conditions
  • Urinary Retention

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Time to Spontaneous Void
Secondary study objectives
Time to Discharge From the Post-anesthesia Care Unit

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Tamsulosin- intervention groupExperimental Treatment1 Intervention
Group II: Placebo groupPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tamsulosin
2002
Completed Phase 4
~16790

Find a Location

Who is running the clinical trial?

University of ArizonaLead Sponsor
536 Previous Clinical Trials
159,569 Total Patients Enrolled
1 Trials studying Urinary Retention
120 Patients Enrolled for Urinary Retention
~34 spots leftby Dec 2025